keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 399.00 |
Description | INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis. |
In vitro | INT-767 does not inhibit hERG, indicating that this compound should not induce cardiac toxicity because of inhibition of the potassium channel[2]. |
In vivo | Mice were treated daily with INT-767 (10 and 20 mg/kg) or vehicle alone (40% 2-hydroxypropyl-β-cyclodextrin) via intraperitoneal injection for 2 weeks. The results showed that INT-767 reduced the levels of plasma total cholesterol, high-density lipoprotein cholesterol, and triglycerides in both db/m and db/db mice [2]. |
Molecular Weight | 494.66 |
Formula | C25H43NaO6S |
CAS No. | 1000403-03-1 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (161.62 mM), Sonification is recommended.
H2O: 80 mg/mL (161.62 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
INT-767 1000403-03-1 GPCR/G Protein Metabolism FXR GPCR19 INT767 INT 767 inhibitor inhibit